“Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2015
Summary
GlobalData’s clinical trial report, 鈥淒ry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2015″” provides an overview of Dry (Atrophic) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data鈥檚 proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Dry (Atrophic) Macular Degeneration 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Dry (Atrophic) Macular Degeneration 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Dry (Atrophic) Macular Degeneration 32
Jul 20, 2015: StemCells Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
F. Hoffmann-La Roche Ltd. 33
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 33
Ocata Therapeutics, Inc. 34
Clinical Trial Overview of Ocata Therapeutics, Inc. 34
Acucela Inc. 35
Clinical Trial Overview of Acucela Inc. 35
Pfizer Inc. 36
Clinical Trial Overview of Pfizer Inc. 36
Otsuka Holdings Co., Ltd. 37
Clinical Trial Overview of Otsuka Holdings Co., Ltd. 37
Ophthotech Corp. 38
Clinical Trial Overview of Ophthotech Corp. 38
Healthcare of Today, Inc. 39
Clinical Trial Overview of Healthcare of Today, Inc. 39
Allergan, Inc. 40
Clinical Trial Overview of Allergan, Inc. 40
Allergan Plc 41
Clinical Trial Overview of Allergan Plc 41
Alexion Pharmaceuticals, Inc. 42
Clinical Trial Overview of Alexion Pharmaceuticals, Inc. 42
Clinical Trial Overview of Top Institutes / Government 43
University of California, Davis 43
Clinical Trial Overview of University of California, Davis 43
Al-Azhar university 44
Clinical Trial Overview of Al-Azhar university 44
Azienda Ospedaliera Pisana 45
Clinical Trial Overview of Azienda Ospedaliera Pisana 45
Dr. Lutfi Kirdar Kartal Training and Research Hospital 46
Clinical Trial Overview of Dr. Lutfi Kirdar Kartal Training and Research Hospital 46
Indian Council of Medical Research 47
Clinical Trial Overview of Indian Council of Medical Research 47
Kaplan Medical Center 48
Clinical Trial Overview of Kaplan Medical Center 48
National Eye Institute 49
Clinical Trial Overview of National Eye Institute 49
University of Kentucky 50
Clinical Trial Overview of University of Kentucky 50
University of Miami 51
Clinical Trial Overview of University of Miami 51
Five Key Clinical Profiles 52
Appendix 95
Abbreviations 95
Definitions 95
Research Methodology 96
Secondary Research 96
About GlobalData 97
Contact Us 97
Disclaimer 97
Source 98″
“List of Tables
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2015* 7
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 15
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 18
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Withdrawn Clinical Trials, 2015* 25
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Terminated Clinical Trials, 2015* 26
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 33
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Ocata Therapeutics, Inc., 2015* 34
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Acucela Inc., 2015* 35
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 36
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Otsuka Holdings Co., Ltd., 2015* 37
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Ophthotech Corp., 2015* 38
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Healthcare of Today, Inc., 2015* 39
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2015* 40
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan Plc, 2015* 41
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Alexion Pharmaceuticals, Inc., 2015* 42
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Davis, 2015* 43
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Al-Azhar university, 2015* 44
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Azienda Ospedaliera Pisana, 2015* 45
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Dr. Lutfi Kirdar Kartal Training and Research Hospital, 2015* 46
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Indian Council of Medical Research, 2015* 47
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaplan Medical Center, 2015* 48
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2015* 49
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Kentucky, 2015* 50
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2015* 51″
“List of Figures
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 15
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 18
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
GlobalData Methodology 96″